Aeon Biopharma News and Activities

Aeon Biopharma is a company listed under the stock ticker AEON (US).

View the org chart displaying its 10 main executives

Most searched biographies at Aeon Biopharma

• Rob Bancroft, President and Chief Executive Officer
• Shelley Thunen, Board Member
• Eric Carter, Director

Popular executive movements at Aeon Biopharma

• John Bencich has joined the company as Chief Financial Officer  (posted on March 10 2026).

Create your alert
to follow the executive moves at Aeon Biopharma.

Aeon Biopharma has 2,415 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Tissium has just announced a $60 Million fundraising (posted on June 25 2026).
• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Aeon Biopharma

• AEON Biopharma - Investors - News
• AEON Biopharma - AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
• AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
• AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
• Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma
• AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
• AEON Biopharma to Host Key Opinion Leader Webinar on Past, Present, and Potential Future Treatments for Migraine on February 24th
• AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
• AEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong Pharmaceutical
• Activating the full potential of therapeutic botulinum toxin | AEON Biopharma
• View more press releases Close

Social media about Aeon Biopharma

• Aeon Biopharma on Wikipedia, Google News & Yahoo Finance
• Aeon Biopharma on LinkedIn, X (Twitter) & YouTube